News Release

Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana

May 2, 2023

INDIANAPOLIS, May 2, 2023 /PRNewswire/ -- To remove barriers and create more equitable, affordable post-high school education opportunities for Indiana's growing immigrant population, Eli Lilly and Company (NYSE: LLY) today announced grants totaling $500,000 to four local nonprofits that offer education assistance to Deferred Action for Childhood Arrivals (DACA) recipients, also known as Dreamers.

Currently, Indiana is one of only two states that does not offer DACA eligible students living in Indiana in-state tuition to its state-run colleges and universities.

"Dreamers deserve the same chance to succeed as their classmates, and right now, many who live in Indiana are unable to afford college because they must pay higher out-of-state tuition fees, which can pose a real challenge for them and their families," said Patrik Jonsson, executive vice president and president of Lilly USA and Lilly Immunology, and chief customer officer.

The grants will go to the following organizations that serve Indiana's immigrant population:

Students can apply for educational assistance through these organizations or through the Central Indiana Community Foundation.

Jonsson continued, "Lilly's support is meant to bridge the gap until more commonsense solutions, including legislation, can remove these higher education barriers for many immigrants in Indiana. Our state's economy needs all our residents to be upskilled to their full potential if we want to meet the demands of the future and stay competitive as a state."

Lilly strongly supports the rights of immigrants, including a pathway to citizenship in the United States for Dreamers. Lilly proudly employs DACA recipients and advocates for sensible immigration reforms that cultivate and support a diverse and skilled workforce.

About Lilly
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram and LinkedIn. C-LLY

Refer to:           Daphne Dorsey,, 317-503-1711

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Cision View original content to download multimedia:

SOURCE Eli Lilly and Company